{"id":"placebo-for-btds-patch","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL521875","moleculeType":"Small molecule","molecularWeight":"460.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo patches are inert transdermal formulations designed to match the appearance and delivery mechanism of active BTDS (buprenorphine transdermal system) patches while containing no active pharmaceutical ingredient. They serve as the control arm in randomized controlled trials to assess the efficacy and safety of the active drug by isolating pharmacological effects from placebo response and study procedures.","oneSentence":"A placebo patch formulation used as a control comparator in clinical trials for transdermal drug delivery systems.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:47.022Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control comparator in clinical trials (not a therapeutic product)"}]},"trialDetails":[{"nctId":"NCT02138357","phase":"PHASE4","title":"Butrans for Treatment of Restless Legs Syndrome","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-04","conditions":"Restless Legs Syndrome","enrollment":""},{"nctId":"NCT01999114","phase":"PHASE1","title":"The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2012-03","conditions":"ECG Effects","enrollment":328},{"nctId":"NCT01259115","phase":"PHASE1","title":"Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2002-10","conditions":"Healthy","enrollment":20},{"nctId":"NCT00531427","phase":"PHASE3","title":"Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2007-09","conditions":"Chronic Pain, Osteoarthritis of the Knee","enrollment":567},{"nctId":"NCT00312195","phase":"PHASE3","title":"Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2001-03","conditions":"Chronic Non-malignant Pain","enrollment":267},{"nctId":"NCT00490919","phase":"PHASE3","title":"Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2007-06","conditions":"Low Back Pain","enrollment":539},{"nctId":"NCT00403234","phase":"PHASE2","title":"Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2006-11","conditions":"Postoperative Pain","enrollment":10},{"nctId":"NCT00315458","phase":"PHASE3","title":"Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.","status":"TERMINATED","sponsor":"Purdue Pharma LP","startDate":"2003-12","conditions":"Osteoarthritis","enrollment":107},{"nctId":"NCT00313846","phase":"PHASE3","title":"Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2003-04","conditions":"Osteoarthritis","enrollment":529},{"nctId":"NCT01141283","phase":"PHASE3","title":"Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2003-04","conditions":"Osteoarthritis","enrollment":290},{"nctId":"NCT00315445","phase":"PHASE3","title":"The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"1997-12","conditions":"Back Pain","enrollment":134},{"nctId":"NCT00345787","phase":"PHASE3","title":"Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Osteoarthritic Pain","status":"COMPLETED","sponsor":"Mundipharma K.K.","startDate":"2006-05","conditions":"Pain, Osteoarthritis","enrollment":262},{"nctId":"NCT00346047","phase":"PHASE3","title":"Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back Pain","status":"COMPLETED","sponsor":"Mundipharma K.K.","startDate":"2006-05","conditions":"Low Back Pain","enrollment":238}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for BTDS patch","genericName":"Placebo for BTDS patch","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo patch formulation used as a control comparator in clinical trials for transdermal drug delivery systems. Used for Control comparator in clinical trials (not a therapeutic product).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}